Zobrazeno 1 - 10
of 26
pro vyhledávání: '"M. Luisa Paccagnella"'
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Purpose: To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35943ae76940aafc27c3ef3e767c0255
https://doi.org/10.1158/1078-0432.c.6524378.v1
https://doi.org/10.1158/1078-0432.c.6524378.v1
Autor:
Anjali S. Advani, A. Douglas Laird, Alexander Neuhof, Erik Vandendries, Barbara Sleight, Kevin Nguyen, M. Luisa Paccagnella, Tao Wang, Matthias Stelljes, Susan M. O'Brien, Elias Jabbour, Daniel J. DeAngelo, Ryan D. Cassaday, Wendy Stock, Hagop M. Kantarjian
Purpose:We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784).Patients and Methods:Adults with relapsed/refractory B-cell prec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf030dd6288dcdbb24ed88988e18f897
https://doi.org/10.1158/1078-0432.c.6530325
https://doi.org/10.1158/1078-0432.c.6530325
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Table S1. Dose Escalation of C (3 levels) or InO (2 levels) and Treatment Schedule Used to Determine the MTD Based on a Standard 3+3 Design; Table S2. AEs Leading to Permanent Discontinuation or Modification of the MTD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292287707d94f0bbbf44fee9335e0ac0
https://doi.org/10.1158/1078-0432.22460018
https://doi.org/10.1158/1078-0432.22460018
Autor:
Anjali S. Advani, A. Douglas Laird, Alexander Neuhof, Erik Vandendries, Barbara Sleight, Kevin Nguyen, M. Luisa Paccagnella, Tao Wang, Matthias Stelljes, Susan M. O'Brien, Elias Jabbour, Daniel J. DeAngelo, Ryan D. Cassaday, Wendy Stock, Hagop M. Kantarjian
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4552990af2a17d599a895f6e51106001
https://doi.org/10.1158/1078-0432.22479924
https://doi.org/10.1158/1078-0432.22479924
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
SUPPLEMENTARY METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680c53c2e6aad14300222af7086c39cd
https://doi.org/10.1158/1078-0432.22460021
https://doi.org/10.1158/1078-0432.22460021
Autor:
Yosuke Fujii, Chul Won Jung, Ming Chung Wang, Barbara Sleight, Miyako Matsumizu, Erik Vandendries, Naohito Fujishima, Kiyoshi Ando, Toshiki Uchida, Chiho Ono, M. Luisa Paccagnella, Masayuki Hino, Yeow Tee Goh, Yasushi Onishi
Publikováno v:
International Journal of Hematology. 110:709-722
Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3 trial comparing InO against
Autor:
Michaela Liedtke, S. M. O'Brien, Jane Liang White, Tao Wang, Matthias Stelljes, Barbara Sleight, M. Luisa Paccagnella, Wendy Stock, Anjali S. Advani, Elias Jabbour, Daniel J. DeAngelo, Nicola Gökbuget, Hagop M. Kantarjian, Erik Vandendries, Giovanni Martinelli
Publikováno v:
American Journal of Hematology. 94:408-416
Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R A
Autor:
Erik Vandendries, Barbara Sleight, Anjali S. Advani, Hagop M. Kantarjian, A. Douglas Laird, Matthias Stelljes, Kevin Nguyen, Alexander Neuhof, Tao Wang, M. Luisa Paccagnella, Wendy Stock, Daniel J. DeAngelo, Ryan D. Cassaday, Elias Jabbour, Susan O'Brien
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(10)
Purpose: We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784). Patients and Methods: Adults with relapsed/refractory B-cell p
Autor:
Michaela Liedtke, Tao Wang, Barbara Sleight, Erik Vandendries, Matthias Stelljes, M. Luisa Paccagnella, Wendy Stock, Susan O'Brien, Anjali S. Advani, Hagop M. Kantarjian, Daniel J. DeAngelo, Nicola Gökbuget, Elias Jabbour
Publikováno v:
Cancer. 124:1722-1732
BACKGROUND Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety
Autor:
Andrew Davies, Kensei Tobinai, Erik Vandendries, Taro Ishibashi, M. Luisa Paccagnella, Michinori Ogura, David MacDonald, Joseph Boni, Kiyohiko Hatake, Michael Crump, Revathi Ananthakrishnan
Publikováno v:
Clinical Cancer Research. 22:4807-4816
Purpose: To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine,